Key takeaways
NovoLog (insulin aspart) and Ozempic (semaglutide) are both medications used to manage diabetes, but they belong to different drug classes and have distinct uses. NovoLog is a fast-acting insulin used to treat both Type 1 and Type 2 diabetes by helping your body absorb sugar from the bloodstream. It is typically injected one or more times a day before meals. On the other hand, Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist used for Type 2 diabetes and to lower the risk of heart problems in adults with Type 2 diabetes and heart disease. It is injected once a week. NovoLog is available in vials and prefilled pens, while Ozempic comes as a prefilled pen. Common side effects of NovoLog include low blood sugar and headaches, whereas Ozempic may cause nausea, vomiting, and diarrhea. NovoLog can lead to weight gain, while Ozempic might cause weight loss. Both medications require careful monitoring of blood sugar levels, and they have different storage requirements and dosing schedules.
